Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Our mission is to develop innovative therapies to address rare and underserved eye diseases

See How

Pursuing Innovative Ocular Biotherapeutics

Ocugen, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The Company offers a robust and diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Ocugen is leveraging its groundbreaking modifier gene therapy platform to address genetically diverse inherited retinal disorders (IRDs) and dry AMD, based on the nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410). OCU400 has received two orphan drug designations (ODD) targeting two distinct IRDs. Ocugen is also developing novel biologic therapies for wet-AMD, DME and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100). The Company's late-stage Phase 3 trial for patients with ocular graft versus host disease (oGVHD) (OCU300) leverages Ocugen’s patented OcuNanoE – Ocugen’s ONE Platform™ technology to enhance the efficacy of topical ophthalmic therapeutics. OCU300 is the first and only therapeutic with ODD for oGVHD, providing certain regulatory and economic benefits.

Explore our pipeline of therapies targeting underserved areas of ophthalmology:

  • OCU300
    For ocular graft versus host disease (oGVHD)
  • OCU400
    For treatment of NR2E3 mutation-associated retinal degeneration
  • OCU200
    For wet age-related macular degeneration

Addressing a common complication that occurs in about 60% of patients who have undergone allogeneic hemotological stem cell transplantation, or bone marrow transplants.

Learn More About OCU300

Addressing a common yet under-diagnosed ocular disorder that affects millions of adults in the US and its prevalence increases with age.

Learn More About OCU310

Addressing a range of genetically diverse inherited degenerative retinal diseases.

Learn More About OCU400

Addressing a group of inherited diseases that cause progressive retinal degeneration, affecting approximately 100,000 people in the US and similar number in Europe.

Learn More About OCU100

Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.

Learn More About OCU200

Press Releases

Explore our pipeline of therapies targeting underserved areas of ophthalmology:

OCU300
For ocular graft versus host disease (oGVHD)

Addressing a common complication that occurs in 40-60% of patients who have undergone allogenic hemotological stem cell transplantation, or bone marrow transplants.

Learn More About OCU300

OCU400
For treatment of NR2E3 mutation-associated retinal degeneration

Addressing a range of genetically diverse inherited degenerative retinal diseases.

Learn More About OCU400
OCU200
For wet age-related macular degneration

Addressing the leading cause of vision loss in people over the age of 60, where abnormal blood vessels grow under the retina and leak blood and proteins.

Learn More About OCU200



Sign up to receive email alerts with the latest news from Ocugen Subscribe